Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals-Reference-Cited by-同舟云学术

Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals

Published:2000-06 Issue:9 Volume:14 Page:1181-1185
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:AIDS

Author:

Rockstroh Jürgen K.,Bergmann Frank,Wiesel Werner,Rieke Ansgar,Theisen Albert,Fätkenheuer Gerd,Oette Mark,Carls Horst,Fenske Stefan,Nadler Mathias,Knechten Heribert

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference11 articles.

1. Treatment of Human Immunodeficiency Virus Infection with Saquinavir, Zidovudine, and Zalcitabine

2. Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy

3. A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less

4. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538)

5. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Cologne–Bonn cohort: lessons learned;Infection;2015-02-24

2. Prevalence, severity, and duration of thrombocytopenia among HIV patients in the era of highly active antiretroviral therapy;Platelets;2011-05-25

3. Stavudine or zidovudine in three-drug combination therapy for initial treatment of HIV infection in antiretroviral-naïve individuals;Cochrane Database of Systematic Reviews;2010-08-04

4. Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen - ANRS 111 trial;Fundamental & Clinical Pharmacology;2009-08

5. Antiretroviral Therapy with a Twice-Daily Regimen Containing 400 Milligrams of Indinavir and 100 Milligrams of Ritonavir in Human Immunodeficiency Virus Type 1-Infected Women during Pregnancy;Antimicrobial Agents and Chemotherapy;2008-04